Indications
Palsonify is indicated for the medical treatment of adult patients with acromegaly.
Composition
- Active substance
- paltusotine hydrochloride
- International name (INN)
- paltusotine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Palsonify
- Active substance
- paltusotine hydrochloride
- ATC code
- H01CB06
- Therapeutic area
- Acromegaly
- Marketing authorisation holder
- Crinetics Pharmaceuticals Europe GmbH
- Status
- Authorised